


General

Cannabinoids and Their Role in Chronic Pain Treatment: Current Concepts and a Comprehensive Review

Islam Shehata¹ , Ahmed Hashim², Ahmed Elsaedy³, Anagha Nair⁴, Ivan Urits⁵, Omar Viswanath⁵, Alan Kaye⁵, Marian Habib⁶

¹ anesthesiology, Ain Shams University, ² Ain Shams University, ³ Benha University, ⁴ Lady Hardinge Medical College, ⁵ Louisiana State University Health Sciences Center, ⁶ Hurghada General Hospital, Department of Cardiology, Hurghada, Egypt

Keywords: Cannabinoids, chronic pain, herbal cannabis, 'hemp' products, pharmaceutical-grade regulated cannabinoid-based medical products

<https://doi.org/10.52965/001c.35848>

Health Psychology Research

Vol. 10, Issue 4, 2022

For decades, chronic pain was managed with an almost conventional approach of using a wide range of analgesic spectrum, surgical approaches and complex interventional pain techniques to modulate or even interrupt pain pathways. These different approaches carry many pharmacological hazards together with the lack of efficacy and safety of many interventional and surgical management techniques for chronic pain have mandated searching for other effective therapies including alternative treatments. Cannabinoids are naturally occurring substances that are derived from *Cannabis sativa* L. The usage of cannabinoids and their related synthetic chemical compounds has emerged as a choice in the management of different chronic pain conditions is being evaluated, however, the efficacy is still not consistently established. In the present investigation, therefore, we discuss the different aspects related to cannabinoids and their implications in the management of chronic pain conditions. This review will also discuss the safety profile of the cannabinoids together with the legal considerations that hinder their use in different countries.

INTRODUCTION

Chronic pain is one of the most distressing conditions that may encounter humans throughout life.¹ The American Academy of Pain Medicine has defined chronic pain as pain that lasts longer than the usual course of an acute injury or disease or the pain that recurs for months or years.² In 2016, it was estimated that 20.4% (50 million) of American adults are suffering from chronic pain with a bad impact on the quality of life for 8.0% of them.³ According to the 11th revision of the International Classification of Diseases (ICD11), chronic pain has been classified into different categories regarding the etiological background present in each condition. For instance, chronic pain may be caused by musculoskeletal abnormalities, advanced malignancy, postsurgical complication, visceral pain, and many different pain conditions.⁴

For decades, chronic pain was managed with an almost conventional approach of using a wide range of analgesic spectrum, ranging from non-steroidal anti-inflammatory drugs (NSAIDs) to weak and strong opioid agonists.⁵ The difficulty and challenges in the management of chronic pain has raised another consideration of using surgical approaches and complex interventional pain techniques to modulate or even interrupt pain pathways.⁶ In this regard, many of the current treatments include the potential of adverse events, including opioid mediated overdose and failure of effective response to injections and to advanced in-

terventional pain therapy techniques. In the United States, chronic use of NSAIDs, which taken chronically can cause asymptomatic gastrointestinal bleeding, has proven to cause nearly 103,000 hospitalizations and 16,500 deaths annually, which is surprisingly comparable to the statistics coming from other well-known disease states and conditions like acquired immune deficiency syndrome (AIDS), asthma, and others.⁷ These risks are conventionally attributed to not only increasing incidence of gastrointestinal bleeding but as well, chronic kidney disease.^{8,9} At present, there is a tragic opioid epidemic, and this is largely understood through different opioid medications stopped natural opioid endogenous production, making people taking long term opioids physically dependent on these exogenous agents, and when stopped, many of these people will pursue opioids that are laced with impurities and fentanyl, include heroin, and other agents that cause respiratory depression and death. In the US, this past year, there were over 83,000 opioid related deaths.^{10,11}

Common side effects of opioid administration include sedation, dizziness, nausea, vomiting, constipation, physical dependence, tolerance, and respiratory depression.¹² Physical dependence and addiction are of particular concern especially in the long-term management of chronic pain conditions. One meta-analysis has reported that the rate of opioid misuse averaged between 21% and 29% and the rate of addiction averaged between 8% and 12% among patients treated with opioids for chronic pain conditions.¹³

These pharmacological hazards together with the lack of efficacy and safety of many interventional and surgical management techniques for chronic pain have mandated searching for other effective therapies including alternative treatments.¹⁴ Cannabinoids are naturally occurring substances that are derived from *Cannabis sativa* L. (*C. Sativa*).¹⁵ The usage of cannabinoids and their related synthetic chemical compounds has emerged as a choice in the management of different chronic pain conditions in the last decade.¹⁶ The use of cannabinoids in a wide spectrum of chronic pain conditions is being evaluated, however, the efficacy is still not consistently established.^{17–19} In the present investigation, therefore, we discuss the different aspects related to cannabinoids and their implications in the management of chronic pain conditions. This review will also discuss the safety profile of the cannabinoids together with the legal considerations that hinder their use in different countries.

METHODOLOGY

A search of literatures published on PubMed from 2017 to 2021 was conducted using keywords including “cannabis”, “THC”, “CBD”, “Nabiximol”, “cancer”, “non-cancer”, “fibromyalgia”, “neuropathic pain” and “pain”. Many clinical studies that evaluated the effect of THC or CBD on controlling different types of pain were evaluated for a selective review. Findings related to study population, interventions, pain response, and side effects were reviewed, summarized, and are presented in [Table \(1\)](#).

PHARMACOKINETICS OF THE CANNABINOIDS

Cannabis describes three separate forms, e.g., herbal cannabis, ‘hemp’ products, pharmaceutical-grade regulated cannabinoid-based medical products (CBMP). Cannabis *sativa* which is the plant form contains hundreds of chemical entities known as phytocannabinoids including Δ^9 -tetrahydrocannabinol (THC), and cannabidiol (CBD) in which have been discovered in the 1960s as the most prevalent bioactive compounds inside cannabis.²⁰ Then they have been extracted and used in different concentrations to formulate many drugs. Effects like impaired memory, learning, motor function, temperature regulation, and psychosis have limited the use of *Cannabis sativa* in clinical practice.²⁰

The pharmacokinetics of THC and CBD and their effects depend on the formulation and route of administration.²¹ The routes of cannabis-based medical uses include smoking cannabis flowers, vaporizing oil formulations, vaporizing ethanolic liquids, vaporizing dry herbs, oro-mucosal administration, oral ingestion of cannabis extracts or edibles, and syqe inhaler.²² **Oral ingestion limits the consistent absorption of both molecules due to their lipophilic nature, which may lead to poor solubility.²² The peak serum concentration for oral oil-based medication occurs approximately 1.5 h after ingestion in a standardized oil-based oral cannabinoid formulation and is at low nontherapeutic levels after 5–6 h.** This makes the bioavailability from the oral

route of approximately 13% and even lower through the oral route (approximately 5%) because of extensive first-pass metabolism.²³

The syqe inhaler is the most effective delivery method for cannabis-based medicine, it reaches the maximum concentration after 3 minutes only.²² Therefore, this emphasizes the importance of the solubilization process of lipophilic drugs such as CBD. These findings offer a standardized oral formulation for the delivery of cannabinoids and contribute data for the growing field of cannabinoid pharmacokinetics.²⁴ The terminal elimination half-life for oral CBD was approximately 70 h, suggesting that 2–3 weeks are needed to fully eliminate CBD.²⁵

THC and CBD are hepatically metabolized, the potential exists for drug interactions via inhibition or induction of cytochrome p450 enzymes or transporters. The metabolism of THC is predominantly hepatic, via cytochrome P450 (CYP 450) isozymes CYP2C9, CYP2C19 and CYP3A4. CBD is also hepatically metabolized, primarily by isozymes CYP2C19 and CYP3A4 and additionally, CYP1A1, CYP1A2, CYP2C9, and CYP2D6. Such pharmacokinetic interactions may occur and care should be taken when prescribing with other hepatically metabolized medications.²⁰ It has been found that cannabis enhances the analgesic effects of opioids, thereby allowing for lower doses.²⁶ Both vulnerable populations, such as older patients, may be at increased risk of adverse effects. There is an overall rarity of studies related to either pharmacokinetic or pharmacodynamic properties for CBMP. Therefore, it is imperative to understand the need to initiate prescribing of CBMP using a ‘start low and go slow’ approach. All patients commenced on CBMP require careful monitoring and observation, particularly the elderly and those with polypharmacy to achieve optimal effects with fewer adverse events.²⁶

ANALGESIC EFFECTS OF CANNABIS, MECHANISM OF ACTION

ENDOCANNABINOID SYSTEM

Cannabinoids exert their analgesic effect by manipulating various pain pathways and molecular mechanisms along with different body systems which are now known as the endocannabinoid system.²⁷ This system includes the whole pathway on which the cannabinoids exert their different actions, including analgesia, from receptors to the transport proteins together with the enzymes responsible for its synthesis and degradation.²⁸ The analgesic effect of either internal or external cannabinoids has been centered around activation of the activity of 2 receptors named cannabinoid receptor1 (CB1R) and cannabinoid receptor 2 (CB2R).²⁹ Both receptors are members of G- protein-coupled receptors that are coupled to pertussis toxin (PTX)-sensitive $G_{i/o}$ protein. On activation of this protein, it inhibits the activity of the adenylate cyclase and subsequently the cyclic AMP production.³⁰ Additionally, CB1R has been linked to activation of other G-proteins families in both cell-type and ligand-dependent manners.³¹ The CB1R is consistently located along the descending and the ascending pain neurons at multiple levels from the

Table 1.

| | | | |
|---|---|--|--|
| Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review | role of the cannabinoid system in chronic inflammatory pain. | it reduce burden of chronic pain | Anthony AT, Rahmat S, Sangle P, Sandhu O, Khan S. Cannabinoid Receptors and Their Relationship With Chronic Pain: A Narrative Review. <i>Cureus</i> . 2020 Sep 14;12(9):e10436. doi: 10.7759/cureus.10436. PMID: 33072446; PMCID: PMC7557112. |
| Use of cannabidiol (CBD) for the treatment of chronic pain | treatment efficacy of CBD, THC,nabiximols for chronic pain and adverse events with each. | | Urits I, Gress K, Charipova K, Habib K, Lee D, Lee C, Jung JW, Kassem H, Cornett E, Paladini A, Varrassi G, Kaye AD, Viswanath O. Use of cannabidiol (CBD) for the treatment of chronic pain. <i>Best Pract Res Clin Anaesthesiol</i> . 2020 Sep;34(3):463-477. doi: 10.1016/j.bpa.2020.06.004. Epub 2020 Jul 2. PMID: 33004159. |
| The Neuroimmunology of Chronic Pain: From Rodents to Humans | neuroimmune signaling mechanisms and novel therapeutic targets in rodent models of chronic pain | | Grace PM, Tawfik VL, Svensson CI, Burton MD, Loggia ML, Hutchinson MR. The Neuroimmunology of Chronic Pain: From Rodents to Humans. <i>J Neurosci</i> . 2021 Feb 3;41(5):855-865. doi: 10.1523/JNEUROSCI.1650-20.2020. Epub 2020 Nov 25. PMID: 33239404; PMCID: PMC7880288. |
| The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial | metered-dose cannabis inhaler delivered precise and low THC doses, produced a dose-dependent and safe analgesic effect in patients with neuropathic pain/ complex-regional pain syndrome (CRPS) | | Almog S, Aharon-Peretz J, Vulfsons S, Ogintz M, Abalia H, Lupo T, Hayon Y, Eisenberg E. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial. <i>Eur J Pain</i> . 2020 Sep;24(8):1505-1516. doi: 10.1002/ejp.1605. Epub 2020 Jun 12. PMID: 32445190; PMCID: PMC7496774. |
| Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain | interactions between cannabinoids and pain medication through drug transporters | morphine,codeine,methadone,tramadol..augment analgesia ...in animals | Vázquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. <i>Biomed Res Int</i> . 2020 Aug 13;2020:3902740. doi: 10.1155/2020/3902740. PMID: 32855964; PMCID: PMC7443220. |
| Cannabis Use in Hospitalized Patients with Chronic Pain | Cannabis use increased substantially from 2011 to 2015 | it improves chronic pain in CRP,Trauma,post surgical,spondylosis | Orhurhu V, Urits I, Olusunmade M, Olayinka A, Salisu Orhurhu M, Uwandu C, Aner M, Ogunsola S, Akpala L, Hirji S, Viswanath O, Karri J, Simopoulos T, Gill J. Cannabis Use in Hospitalized Patients with Chronic Pain. <i>Adv Ther</i> . 2020 Aug;37(8):3571-3583. doi: 10.1007/s12325-020-01416-9. Epub 2020 Jul 6. PMID: 32632850; PMCID: PMC7370966. |

| | | | |
|---|--|---|--|
| Cannabis Use and Low-Back Pain: A Systematic Review | analgesic for low-back pain | more research regarding their analgesic effect is needed | First L, Douglas W, Habibi B, Singh JR, Sein MT. Cannabis Use and Low-Back Pain: A Systematic Review. <i>Cannabis Cannabinoid Res.</i> 2020 Dec 15;5(4):283-289. doi: 10.1089/can.2019.0077. PMID: 33381642; PMCID: PMC7759283. |
| Understanding Cannabis-Based Therapeutics in Sports Medicine | treatment for athletes with chronic pain conditions | difficult for the sport medicine clinicia to recommed cbd dt limited research | Maurer GE, Mathews NM, Schleich KT, Slayman TG, Marcussen BL. Understanding Cannabis-Based Therapeutics in Sports Medicine. <i>Sports Health.</i> 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604. Epub 2020 Sep 16. PMID: 32936058; PMCID: PMC7785900. |
| Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia | cannabis in fibromyalgia:risk benefit | its usage is limited | Berger AA, Keefe J, Winnick A, Gilbert E, Eskander JP, Yazdi C, Kaye AD, Viswanath O, Urits I. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. <i>Best Pract Res Clin Anaesthesiol.</i> 2020 Sep;34(3):617-631. doi: 10.1016/j.bpa.2020.08.010. Epub 2020 Aug 15. PMID: 33004171. |
| Analgesic Effects and Impairment in Locomotor Activity Induced by Cannabinoid/Opioid Combinations in Rat Models of Chronic Pain | antinociceptive effect of combining synthetic cannabinoids with subtherapeutic doses of opioids | t WIN55212 in combination with tramadol produced a significant reduction in the nociceptive response | Alsalem M, Altarifi A, Haddad M, Azab B, Kalbouneh H, Imraish A, Saleh T, El-Salem K. Analgesic Effects and Impairment in Locomotor Activity Induced by Cannabinoid/Opioid Combinations in Rat Models of Chronic Pain. <i>Brain Sci.</i> 2020 Aug 6;10(8):523. doi: 10.3390/brainsci10080523. PMID: 32781705; PMCID: PMC7547378. |
| Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control | medical cannabis to support opioid tapering | safe introduction and titration of cannabinoids in concert with tapering opioids. | Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, Clarke H, Cooper ZD, Cyr C, Daeninck P, Deshpande A, Ethans K, Flusk D, Le Foll B, Milloy MJ, Moulin DE, Naidoo V, Ong M, Perez J, Rod K, Sealey R, Sulak D, Walsh Z, O'Connell C. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. <i>Int J Clin Pract.</i> 2020 Nov 28:e13871. doi: 10.1111/ijcp.13871. Epub ahead of print. PMID: 33249713. |
| [Medical cannabinoids and their indications in chronic pain] | Its use is only validated in certain limited cases, in particular spasticity linked to multiple sclerosis and refractory epilepsies. All other prescriptions require a special request to the OFSP | cannabis use is only validated in certain limited cases, in particular spasticity linked to multiple sclerosis and refractory epilepsies. All other prescriptions require a special request to the OFSP. Moreover, cannabinoid intake may produce several dose-dependent side effects | El Faleh-Kayal Y, Suter M, Cachemaille M. Les cannabinoïdes et leurs indications en antalgie chronique [Medical cannabinoids and their indications in chronic pain]. <i>Rev Med Suisse.</i> 2020 Jul 15;16(700):1363-1366. French. PMID: 32672015. |

| | | | |
|--|---|--|--|
| Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? | cannabs in chronic musculoskeletl pain | cannabinoids Therapeutic Advances in Musculoskeletal Disease may be considered as an adjunctive therapy after recommended first- and second-line therapies have failed to provide sufficient efficacy or tolerability | Johal H, Vannabouathong C, Chang Y, Zhu M, Bhandari M. Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? <i>Ther Adv Musculoskelet Dis.</i> 2020 Jul 2;12:1759720X20937968. doi: 10.1177/1759720X20937968. PMID: 32655704; PMCID: PMC7333482. |
| Cannabinoids in the Treatment of Back Pain | potential role of cannabinoids in the treatment of back pain. | The significant risk of morbidity, mortality, and dependence secondary to opioid medications have increased the interest in nonopioid medications | Kim TE, Townsend RK, Branch CL, Romero-Sandoval EA, Hsu W. Cannabinoids in the Treatment of Back Pain. <i>Neurosurgery.</i> 2020 Aug 1;87(2):166-175. doi: 10.1093/neuros/nyz573. PMID: 32097466. |
| Cannabinoid and Opioid Use Among Total Joint Arthroplasty Patients: A 6-Year, Single-Institution Study | total joint arthroplasty pts cannabinoid versus opioid | During a 6-year period, cannabinoid use increased more than 60%, and opioid use decreased approximately 30%. | Denduluri SK, Woolson ST, Indelli PF, Mariano ER, Harris AHS, Giori NJ. Cannabinoid and Opioid Use Among Total Joint Arthroplasty Patients: A 6-Year, Single-Institution Study. <i>Orthopedics.</i> 2021 Jan 1;44(1):e101-e106. doi: 10.3928/01477447-20200928-02. Epub 2020 Oct 1. PMID: 33002174. |
| Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management | episodic vomiting | It is characterized by stereotypical episodic vomiting in the setting of chronic, daily cannabis use, with cycles decreasing by the cessation of cannabis | Gajendran M, Sifuentes J, Bashashati M, McCallum R. Cannabinoid hyperemesis syndrome: definition, pathophysiology, clinical spectrum, insights into acute and long-term management. <i>J Investig Med.</i> 2020 Dec;68(8):1309-1316. doi: 10.1136/jim-2020-001564. Epub 2020 Oct 28. PMID: 33115959. |
| Use of Cannabis for Self-Management of Chronic Pelvic Pain | cannabidiol in chronic pelvic pain | improvement in symptoms, including pain, cramping, muscle spasms, anxiety, depression, sleep disturbances, libido, and irritability. | Carrubba AR, Ebbert JO, Spaulding AC, DeStephano D, DeStephano CC. Use of Cannabis for Self-Management of Chronic Pelvic Pain. <i>J Womens Health (Larchmt).</i> 2020 Nov 16. doi: 10.1089/jwh.2020.8737. Epub ahead of print. PMID: 33252316. |
| Cannabis: are there any benefits? | herbal:THC,CBD,Medical:CKMB more benefits | CBMP:pharmacology,evidence,SE | Vickery AW, Finch PM. Cannabis: are there any benefits? <i>Intern Med J.</i> 2020 Nov;50(11):1326-1332. doi: 10.1111/imj.15052. PMID: 33215831. |
| Cannabinoid use among Americans with MS: Current trends and gaps in knowledge | THC and CBD in MS | Benefit from cannabinoids for sleep and pain were strongly correlated ($r = 0.65$, $p < 0.0001$) | Bralely TJ, Whibley D, Alschuler KN, Ehde DM, Chervin RD, Clauw DJ, Williams D, Kratz AL. Cannabinoid use among Americans with MS: Current trends and gaps in knowledge. <i>Mult Scler J Exp Transl Clin.</i> 2020 Sep 22;6(3):2055217320959816. doi: 10.1177/2055217320959816. PMID: 33014410; PMCID: PMC7518014. |

| | | | |
|---|--|---|---|
| Current application of cannabidiol (CBD) in the management and treatment of neurological disorders | anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders>>>>Cannabidiol | CBD has shown promise in the treatment of neurological disorders such as anxiety, chronic pain, trigeminal neuralgia, epilepsy, and essential tremors as well as psychiatric disorders | Fiani B, Sarhadi KJ, Soula M, Zafar A, Quadri SA. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. <i>Neurol Sci.</i> 2020 Nov;41(11):3085-3098. doi: 10.1007/s10072-020-04514-2. Epub 2020 Jun 16. PMID: 32556748. |
| Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression | cannabinoids in neuropathic versus non neuropathic pain | mean pain score (scale 0-10) reduction of -0.70 (p < 0.001, random effect). Meta-regression showed that analgesic efficacy was similar for neuropathic and non-neuropathic pain (Difference = -0.14, p = 0.262 | Wong SSC, Chan WS, Cheung CW. Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression. <i>J Neuroimmune Pharmacol.</i> 2020 Dec;15(4):801-829. doi: 10.1007/s11481-020-09905-y. Epub 2020 Mar 14. PMID: 32172501. |
| CBD for the treatment of pain: What is the evidence? | why CBD IS better | there is insufficient evidence to recommend CBD for the treatment of pain | Svensson CK. CBD for the treatment of pain: What is the evidence? <i>J Am Pharm Assoc</i> (2003). 2020 Nov-Dec;60(6):e80-e83. doi: 10.1016/j.japh.2020.06.009. Epub 2020 Jul 4. PMID: 32636158. |
| Cannabinoids in multiple sclerosis: A neurophysiological analysis | oral spray containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in MS | The THC-CBD spray improved spasticity and pain in secondary progressive MS patients. | Vecchio D, Varrasi C, Virgilio E, Spagarino A, Naldi P, Cantello R. Cannabinoids in multiple sclerosis: A neurophysiological analysis. <i>Acta Neurol Scand.</i> 2020 Oct;142(4):333-338. doi: 10.1111/ane.13313. Epub 2020 Jul 21. PMID: 32632918. |
| Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review | mechanisms of action of the phytocannabinoids, especially THC and CBD. the indications and adverse effects | THC acts as a partial agonist at cannabinoid 1/2 receptors (CB1/2). It is responsible for the characteristic effects of cannabis, such as euphoria, relaxation, and changes in perceptions. THC can also produce dysphoria, anxiety, and psychotic symptoms. . CBD acts as a noncompetitive negative allosteric modulator of the CB1 receptor, as an inverse agonist of the CB2 receptor, and as an inhibitor of the reuptake of the endocannabinoid anandamide.. CBD does not produce the typical effects associated with THC. | Dos Santos RG, Hallak JEC, Crippa JAS. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. <i>Adv Exp Med Biol.</i> 2021;1264:29-45. doi: 10.1007/978-3-030-57369-0_3. PMID: 33332002. |
| Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians | cannabinoids' diverse mechanisms of action as it pertains to nociception modulation | Cannabinoids-opioids cross-modulation and synergy contribute significantly to tolerance and antinociceptive effects of cannabinoids. 'cb diverse mechanisms of action as it pertains to nociception modulation | Narouze S. Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians. <i>Reg Anesth Pain Med.</i> 2021 Mar;46(3):240-250. doi: 10.1136/rapm-2020-102114. Epub 2020 Nov 25. PMID: 33239391. |
| Medical cannabis and cognitive performance in middle to old adults treated for chronic pain | long-term medical cannabis (MC) use and cognitive function | whole plant MC does not have a widespread impact on cognition in older chronic pain patients | Sznitman SR, Vulfsons S, Meiri D, Weinstein G. Medical cannabis and cognitive performance in middle to old adults treated for chronic pain. <i>Drug Alcohol Rev.</i> 2021 Feb;40(2):272-280. doi: 10.1111/dar.13171. Epub 2020 Sep 22. PMID: 32964502. |

| | | | |
|--|----------------------------------|--|---|
| Sex differences and the endocannabinoid system in pain | | Female rodents have generally been found to be more sensitive to the effects of Δ^9 -THC | Blanton HL, Barnes RC, McHann MC, Billbrey JA, Wilkerson JL, Guindon J. Sex differences and the endocannabinoid system in pain. <i>Pharmacol Biochem Behav.</i> 2021 Mar;202:173107. doi: 10.1016/j.pbb.2021.173107. Epub 2021 Jan 12. PMID: 33444598; PMCID: PMC8216879. |
| Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population | THC and CBD in palliative | Approximately a quarter of outpatient palliative care patients use THC or CBD, often on a daily basis. | Hight BH, Lesser ER, Johnson PW, Kaur JS. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population. <i>Am J Hosp Palliat Care.</i> 2020 Aug;37(8):589-593. doi: 10.1177/1049909119900378. Epub 2020 Jan 27. PMID: 31986898. |
| Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | thc rich oil in fibromyalgia | the cannabis group presented a statistically significant reduction, going from 75.5 to 30.5 points ($P < 0.001$). At the same time, the placebo group maintained its score ($P = 0.07$). Furthermore, in an isolated analysis of FIQ items, the cannabis group presented a reduction in mean values on the "feel good," "pain," and "fatigue" items. The placebo group presented a reduction in mean values on the "depression" item | Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Pain Med.</i> 2020 Oct 1;21(10):2212-2218. doi: 10.1093/pm/pnaa303. PMID: 33118602; PMCID: PMC7593796. |
| The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence | synergy with morphine | cannabinoid CB2 receptor activation enhances the therapeutic properties of opioids while attenuating unwanted side-effects such as reward and dependence that occur with sustained opioid treatment. | Iyer V, Slivicki RA, Thomaz AC, Crystal JD, Mackie K, Hohmann AG. The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. <i>Eur J Pharmacol.</i> 2020 Nov 5;886:173544. doi: 10.1016/j.ejphar.2020.173544. Epub 2020 Sep 5. PMID: 32896549; PMCID: PMC7694697. |
| Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside | | | Meng H, Deshpande A. Cannabinoids in chronic non-cancer pain medicine: moving from the bench to the bedside. <i>BJA Educ.</i> 2020 Sep;20(9):305-311. doi: 10.1016/j.bjae.2020.05.002. Epub 2020 Jul 21. PMID: 33456965; PMCID: PMC7807923. |
| Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease | cannabinoid in alzheimer disease | Cannabinoids act by targeting several signaling processes, such as pain, abnormal processing of Ab and tau, neuroinflammation, excitotoxicity, oxidative stress, and mitochondrial dysfunction, which play a pivotal role in the management of AD. Cannabinoids also ameliorate behavioral and cognitive dysfunctions. T | Uddin MS, Mamun AA, Sumsuzzman DM, Ashraf GM, Perveen A, Bungau SG, Mousa SA, El-Seedi HR, Bin-Jumah MN, Abdel-Daim MM. Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease. <i>Front Pharmacol.</i> 2020 Jul 22;11:1097. doi: 10.3389/fphar.2020.01097. PMID: 32792944; PMCID: PMC7387504. |

| | | | |
|--|-----------------------------|--|---|
| <p>Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials</p> | | <p>This review concludes that cannabinoids may have a potential role in chronic pain management</p> | <p>Longo R, Oudshoorn A, Befus D. Cannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials. <i>Pain Manag Nurs.</i> 2021 Apr;22(2):141-149. doi: 10.1016/j.pmn.2020.11.006. Epub 2021 Jan 19. PMID: 33353819.</p> |
| <p>General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews</p> | | <p>harms associated with cannabis and cannabinoids generally relevant to individuals being treated for pain. including psychiatric and psychosocial harms, cognitive/behavioral effects, motor vehicle accidents, cardiovascular, respiratory, cancer-related, maternal/fetal, and general harms</p> | <p>Mohiuddin M, Blyth FM, Degenhardt L, Di Forti M, Eccleston C, Haroutounian S, Moore A, Rice ASC, Wallace M, Park R, Gilron I. General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. <i>Pain.</i> 2021 Jul 1;162(Suppl 1):S80-S96. doi: 10.1097/j.pain.0000000000002000. PMID: 32941319.</p> |
| <p>The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage</p> | <p>cannabis and opioids</p> | <p>cannabis use worked as an alternative to prescription opioids in just over half of patients with low back pain and as an adjunct to diminish use in some chronic opioid users.</p> | <p>Takakuwa KM, Hergenrather JY, Shofer FS, Schears RM. The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain: How Cannabis Diminished Prescription Opioid Usage. <i>Cannabis Cannabinoid Res.</i> 2020 Sep 2;5(3):263-270. doi: 10.1089/can.2019.0039. PMID: 32923663; PMCID: PMC7480723.</p> |

peripheral neuronal terminal to the supraspinal level including the dorsal root ganglion, a critical relay station for pain neuronal pathway. Unlike CB1R, CB2R has been strongly recognized as both peripheral and central cannabinoids receptor that is located within the numerous peripheral tissue types within a recognizable expression on the inflammatory cells.³²⁻³⁴ The location of the CB2R on the nervous system has been linked to the pain-related areas including the cerebral cortex, hippocampus, striatum, amygdala, and thalamic nuclei.^{28,35} One of the basic mechanisms by which the different cannabinoids receptors exert their analgesic effect is through modulation of pain impulse transmission through modifying the release of the neurotransmitter at the synaptic cleft.²⁷ For instance, 2-acyl glycerol (2-AG) which is one of the internal cannabinoids, is usually synthesized as a response to increased intracellular calcium. Upon production, it is transported retrogradely to interact with the presynaptic cannabinoid's receptors.^{27,36} When activated, CB1R suppresses the release of the chemical neurotransmitters through inactivating the presynaptic voltage-gated calcium channels and inhibition of the adenylate cyclase.^{36,37}

NON-CANNABINOIDS RECEPTOR EFFECTS

Besides ameliorating pain by interaction with CB1R and CB2R, it has been shown that cannabinoids can carry out their analgesic effect through other non-CB1R / CB2R G protein-coupled receptors.^{38,39} These other G-protein coupled receptors include opioid and serotonin receptors.^{40,41} Additionally, O'Sullivan has reported that cannabinoids can exert nuclear effects through the modulation of peroxisome proliferator-activated receptors (PPARs).⁴² More recently, multiple studies have demonstrated the potential role of cannabinoids in activating the membrane ion channels, specifically transient receptor potential channels (TRP).^{43,44}

ANTI-INFLAMMATORY EFFECTS

In addition to the abovementioned neuronal effects, a piece of growing evidence suggests that the analgesic effect may be also attributed to its action on the process of inflammation itself.^{45,46} The anti-inflammatory effect of cannabinoids, hence analgesic, is attributed to the multiple mechanisms that affect the different aspects of the process of inflammation. Indeed, ablation of CB2R on a colitis animal model has shown an increase in the inflammatory activity within the macrophage.⁴⁷ The exaggeration of the inflammatory effect was similarly noted in encephalomyelitis after knocking down the CB2R.⁴⁸ Additionally, cannabinoids have also been reported to decrease the production of inflammatory cytokines by interfering with the action of inflammasome and inducing autophagy of the inflammatory cells.⁴⁹ In the last decades, many studies have demonstrated that tetrahydrocannabinol is 80 times more potent than aspirin and two times more hydrocortisone in decreasing the inflammatory reaction.^{50,51} Cannabinoids have also demonstrated enhancement of the apoptosis of the inflammatory cells through activation of caspases upon binding

to their respective receptors.⁵² Similarly, it has also been shown to decrease the expression of major histocompatibility molecules on the surface of the splenic dendritic cells.⁵³ The cannabinoids have also been shown to decrease the production of inflammatory cytokines such as IL-6 that is readily implicated in multiple autoimmune conditions such as systemic lupus erythematosus and rheumatoid arthritis.⁵⁴ Additionally, cannabinoids have also demonstrated inhibitory activity against LPS-stimulated mRNA expression of IL-1 α , IL-1 β , IL-6, and TNF- α in cultured microglial cells of a rat.⁵⁵

Therefore, it's imperative to understand that the analgesic effect of the cannabinoids may be strongly attributed to modulating both ascending and descending pain pathways together with strongly suppressing the associated inflammation in multiple chronic pain conditions. The mechanism of suppressing the inflammatory process may be attributed to a decrease in the production of inflammatory cytokines, suppression of the inflammatory implicated enzymes and even inducing apoptosis of the inflammatory cells.

POTENTIAL USES OF MEDICAL CANNABIS IN PAIN MANAGEMENT

CANNABINOIDS AND NEUROPATHIC PAIN

Neuropathic pain may be due to small nerve fiber involvement as in diabetes, or nerve impingement like radiculopathy or sciatica. There are many standard medical therapies for the management of neuropathic pain. However, THC- oromucosal spray or oil showed a beneficial impact even in refractory cases.⁵⁶

A randomized controlled study was conducted on Seventeen patients with chronic lumbar radicular pain who were assigned to receive either THC oil or placebo oil. The study showed a significant reduction in the pain in the THC group compared to the placebo group. THC-induced analgesia was correlated with a reduction in functional connectivity between the anterior cingulate cortex (ACC) and the sensorimotor cortex.⁵⁷ In addition, Xu et al. conducted another randomized, placebo-controlled trial involving 29 patients with peripheral neuropathy of different etiologies. The patients were randomly divided to receive either cannabis oil or emu oil for 4 weeks, then the cases group are allowed to cross over and receive the placebo. There was a statistically significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo. However, the deep pain showed statistically insignificant improvement.⁵⁸

Regarding multiple sclerosis, Amerongen et al conducted a double-blind, placebo-controlled, crossover trial including 24 patients who have progressive multiple sclerosis with moderate spasticity. Spasticity and pain appear to be influenced by D9-THC through higher-level central nervous system modulation of perception of spasticity rather than electrophysiologic muscle spasticity itself. Accordingly, ECP002A (which is an oral formulation of d THC) may have a role in the symptomatic treatment of spasticity and pain in multiple sclerosis.⁵⁹

CANNABINOIDS IN CANCER PAIN

Cancer pain affects the quality of patients' life and represents a major economic burden across the world. Unfortunately, opioid therapy and other conventional analgesic modalities don't show complete relief of pain in many patients. Various studies have been conducted to evaluate the potential use of CBD and nabiximol in cancer patients.⁵⁶ A study conducted in 2018 by Lichtman et al., assessed using the oral spray of Nabiximol in advanced cancer patients with chronic pain.⁶⁰ They included the patients with average pain Numerical Rating Scale scores ≥ 4 and ≤ 8 despite optimized opioid therapy. They found a median percent improvement in average score in the nabiximol group 10.7 versus 4.5% in the placebo group. Moreover, Nabiximol was statistically superior to placebo on two of three quality-of-life instruments which advocated its usage in patients with early tolerance to opioid therapy.

CANNABINOIDS IN OSTEOARTHRITIS

In a randomized placebo-controlled, double-blinded study conducted on a spontaneous canine model of osteoarthritis, Verrico et al found that CBD significantly decreased pain and increased mobility in a dose-dependent fashion among animals.⁶¹

CANNABIS IN FIBROMYALGIA

Fibromyalgia is characterized by multifocal points of pain, a sense of fatigue, and psychiatric symptoms like depression. Although many studies showed improvement of the symptoms after cannabis use, no clinical evidence regarding its use at the time being.⁶² Tine van et al., assessed the short-term analgesic effects of inhaled pharmaceutical-grade cannabis in 20 chronic pain patients with fibromyalgia. They tested three different cannabis (Bedrocan, Bediol, and Bedrolite) with different concentrations of THC and CBD versus placebo on the different pain stimuli.⁶³ They found none of the active treatments were effective in reducing spontaneous pain scores more than placebo. However, the Group of Bediol (which contains a high concentration of THC) displayed a 30% decrease in spontaneous pain scores compared to placebo (90% vs 55% of patients, P50.01). Therefore, further studies are needed to determine the long-term treatment effects on pain score and investigate the THC-CBD interactions.

On the other hand, a multicenter, double-blind, randomized, placebo-controlled, parallel-group study proved the benefit of THC-rich cannabis oil (24.44 mg/mL of THC and 0.51mg/mL of cannabidiol [CBD]) on symptoms and quality of life of patients who have fibromyalgia in Brazil. In this study, 20 patients with fibromyalgia were randomly assigned to take either cannabis oil or olive oil. After 8 weeks, the cannabis group presented a significant decrease in FIQ (Fibromyalgia Impact Questionnaire) score in comparison with the placebo group ($P < 0.001$). The more interesting finding is that the cannabis group presented a significant improvement on the "feel good," "pain," "do work,"

and "fatigue" scores, which promote using cannabis as a herbal medicine option for the treatment of fibromyalgia.²⁰

SIDE EFFECTS

CARDIOVASCULAR SYSTEM

Tachycardia and hypertension are the most frequently reported Cardiovascular side effects of cannabinoids while bradycardia and hypotension are rarely reported in 116 patients studied.⁶⁴ Three clinical trials stated dose-dependent increases in heart rate but two of them stated a decrease in blood pressure: one in systolic pressure and the other one in diastolic pressure.⁶⁵⁻⁶⁷ However, one of the disadvantages is the low number of participants in these clinical trials. Another cohort of 7500 Australians estimated a significant 2.3-fold increase in stroke risk in Cannabis users.⁶⁸ Moreover, a French cohort declared a significant Association between cannabis use and multifocal intracranial stenosis.⁶⁹

The assessment of lifetime cannabis use and dose-response effects found no association with cardiovascular mortality, stroke, and coronary heart disease.⁷⁰ Although weekly cannabis use has been associated with an increased risk for cardiovascular mortality, there is no evidence for an increase in all-cause mortality.^{64,70,71} Finally, Atrial fibrillation after cannabis smoking was reported and Buerger disease, a rare form of arteritis, may be linked with cannabis use.^{72,73}

RESPIRATORY SYSTEM

The risk of Cough, sputum production, wheezing, dyspnea, and bronchitis increase in cannabis smokers.⁷⁴ In addition, many cases of emphysema, chronic obstructive lung disease (COPD), and lung hyperinflation were found with insufficient evidence of obstructed airflow.⁷⁵ Moreover, chest tightness, phlegm production, and pulmonary infections such as tuberculosis, legionnaires disease, aspergillosis, and other opportunistic infections may be associated with cannabis smoking.^{74,75} Bronchial biopsies showed precancerous lung changes such as increased mitotic activity, squamous cell metaplasia, and columnar cells are indicated in non-tobacco-smoking cannabis smokers.⁷⁶ There is no conclusive evidence about lung bullae in cannabis smokers and airway hyperactivity or lung function in long-term cannabis smoking.^{77,78}

PSYCHIATRIC DISORDERS

The risk of suicidal ideation behavior, suicide attempt, and suicide death are increased with the use of cannabinoids.^{79,80} Cannabis use also increases the psychosis risk and reduces its onset age by about 2.7 years.⁸¹⁻⁸³ Psychotic-like events are associated with cannabis in a dose-response manner inducing the risk of schizophrenia.^{84,85} Moreover, cannabis use is associated with aggravating the severity of symptoms, and less Remission depression, mania, panic or social phobia, post-traumatic stress disorder, and anxiety.⁸⁶

Many systematic reviews and meta-analyses have stated neurocognitive impairment with cannabis use including reasoning, association, flexibility, speed of information processing, verbal memory, language, motor inhibition, conceptual set-shifting, attention, working memory, learning impairments, visuospatial abilities, motor functioning, executive function/abstraction, verbal immediate recall, verbal delayed recall, verbal recognition, prospective memory, total memory, visual learning, verbal learning, prospective event-based and time-based Memories, forgetting, perceptual-motor and reaction time.^{86–95}

CARCINOGENIC SIDE EFFECTS

Cannabis use increases the risk of non-seminoma testicular germ cell tumor (TGCT), and with insufficient evidence, oral, Pharyngeal, lung, and esophageal cancers.^{96,97} However, some studies showed no increased risk of head and neck cancer, anal, penile, seminoma-TGCT, non-Hodgkin lymphoma, colorectal, or overall cancer. However, an increased risk for primary glioma, cervical, testicular, prostate, bladder, and oropharyngeal cancer, was proved in non-tobacco-smoking cannabis users. In addition, increased risks of childhood leukemia, astrocytoma, rhabdomyosarcoma, and neuroblastoma were weakly associated with parental use of cannabis, in pediatric cancers.^{98–100}

MATERNAL AND FETAL SIDE EFFECTS

There is no clear strong evidence about the prenatal side effects of cannabis use. However, prenatal cannabis use seems to have potentially harmful effects on neuropsychological functioning.¹⁰¹ Moreover, a meta-analysis indicated low birth weight as a side effect of prenatal cannabis use.¹⁰² Other studies related reduced neonatal length, gestational age, head circumference, longer stay neonatal intensive care unit, and maternal anemia to using cannabis.¹⁰³

SYNTHETIC CANNABINOID (SC) SIDE EFFECTS

Many studies have shown different adverse effects linked to SC intoxication. These effects include impairments in motor functioning, attention and response inhibition, impairments in working memory, long-term memory.¹⁰⁴ Moreover, the adverse effects may involve hypertension, tachycardia, nausea, vomiting agitation, seizures, hallucinations, delusions, psychosis, hypokalemia, abdominal pain, hyperglycemia, and leukocytosis.^{105–107} Other studies have found an association between kidney damage and SC use.¹⁰⁷ The SC-induced renal impairment may include acute interstitial nephritis, acute tubular necrosis, rhabdomyolysis, Chronic use may lead to severe prerenal azotemia.¹⁰⁸

CANNABIS ADDICTION

Cannabinoid abuse has increased concomitantly with the growing legalization of cannabis use worldwide. Long-term cannabinoid use (especially if started at a young age) may

cause addiction which results in withdrawal syndrome with stopping the chronic cannabinoid use.¹⁰⁹ Diagnostic and Statistical Manual of Mental Disorders (DSM-5) defined Cannabis use disorder as a pathological pattern including tolerance, social and control impairment, and physiological adaptation. Cannabis withdrawal symptoms are like tobacco withdrawal symptoms including depression, anger, irritability, difficulty sleeping, and decreased appetite. These symptoms have been presented after one or two days of Cannabis use stoppage and may last to two weeks.^{110–112} These symptoms' intensity varies according to the amount and the potency of cannabis use before discontinuation. Mild to moderate symptoms can be managed in the outpatient detoxification settings reserving hospitalization for severe symptoms.¹¹³ Many modalities have been studied to treat cannabis withdrawal symptoms. Cannabidiol is an aspiring treatment for the withdrawal syndrome because of its safety, tolerability, pharmacological effects on endocannabinoids (inhibit endocannabinoids hydrolysis and reuptake), and interaction with tetrahydrocannabinol effects. A clinical trial has stated that cannabidiol doses (400 and 800 mg) as effective safe doses to reduce cannabis use.¹¹⁴ Nicotine patches, a 7 mg dose, showed the ability to reduce the withdrawal symptoms in patients with cannabis use disorder who are not nicotine dependent or not heavy cannabis users.¹¹⁵

In addition, exogenous progesterone may reduce the withdrawal symptoms in women with acute symptoms as it reduces cannabis craving. However, long-term-large studies are required to approve its use.¹¹⁶ Although oral tetrahydrocannabinol, lofexidine, nabiximols, and nefazodone reduced depressed mood, anxiety, sleep disorders, and craving, these drugs worsened some withdrawal symptoms as irritability.^{117,118} Till now, the main approach to treat the withdrawal symptoms of cannabis use is the psychotherapeutic techniques with no approved drugs for the treatment of cannabis dependence.¹¹⁹

LEGAL ISSUES OF CANNABIS

Globally, Cannabis legalization has supporters who believe that it will improve public health, reduce criminal justice expenditure, and stimulate the economy. On the other hand, critics see that the legalization will increase cannabis use affecting health and safety, reducing the educational achievement of teens, and increasing crime.¹²⁰ Food and Drug Administration (FDA) has approved only a cannabis-derived drug (Epidiolex (cannabidiol)) and three synthetic cannabis (Marinol and Syndros (dronabinol) and Cesamet (nabilone)). Also, FDA classified cannabis in Schedule I which contains substances with high potentials for abuse. Consequently, conducting cannabis-related clinical trials is complicated. Also, medical-based cannabis and cannabinoids use must be only in necessity and supervised by medical staff.^{121,122}

In the USA, Cannabis use is federally illegal. However, nine states have legalized recreational cannabis use for adults since 2012. Also, Canada legalized medical-based cannabis use in 1999 and recreational use in 2018. In 2019,

The UK legalized medical-based cannabis use in addition to many other countries. Consequently, this should encourage conduction more studies to understand the effect of cannabis in pain management.^{123–126}

CONCLUSION

Cannabinoids and their related chemical compounds may play a substantial role in managing different types of chronic pain. Being a natural product with many routes of administration may raise it as a potential alternative for various pain conditions. The cannabinoids related compounds exert their effects by the diverse and versatile mechanisms of action that include both the neuronal and inflammatory pathways. cannabinoids have been studied in

different cases of chronic pain with considerable tolerability. However, there was inconsistent efficacy endpoint that mandate further studies to estimate the actual efficacy of cannabinoids in the management of chronic pain disorders. Cannabinoid's usage was also associated with adverse effects. Addiction among the treated patients is still the major concern especially when the doses are adjusted by the medical profession. This hazard raises a strong legal consideration of a wide application of the cannabinoids related compounds in the management of chronic pain. Therefore, its imperative to discuss social, legal, and medical aspects to weigh public risks and concerns related to the usage of cannabinoids in comparison to the expected benefits on the patient's quality of life.

Submitted: May 18, 2022 EST, Accepted: May 18, 2022 EST

REFERENCES

1. Fine PG. Long-term consequences of chronic pain: mounting evidence for pain as a neurological disease and parallels with other chronic disease states. *Pain Med.* 2011;12(7):996-1004. doi:10.1111/j.1526-4637.2011.01187.x
2. Raffaelli W, Arnaudo E. Pain as a disease: an overview. *J Pain Res.* 2017;10:2003-2008. doi:10.2147/JP.R.S138864
3. Dahlhamer J, Lucas J, Zelaya C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR Morb Mortal Wkly Rep.* 2018;67(36):1001-1006. doi:10.15585/mmwr.mm6736a2
4. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. *Pain.* 2015;156(6):1003-1007. doi:10.1097/j.pain.0000000000000160
5. Beal BR, Wallace MS. An Overview of Pharmacologic Management of Chronic Pain. *Med Clin North Am.* 2016;100(1):65-79. doi:10.1016/j.mcna.2015.08.006
6. Hylands-White N, Duarte RV, Raphael JH. An overview of treatment approaches for chronic pain management. *Rheumatol Int.* 2017;37(1):29-42. doi:10.1007/s00296-016-3481-8
7. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. *Clin Gastroenterol Hepatol.* 2005;3(1):55-59. doi:10.1016/s1542-3565(04)00603-2
8. Castellsague J, Pisa F, Rosolen V, et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. *Pharmacoepidemiol Drug Saf.* 2013;22(4):365-375. doi:10.1002/pds.3385
9. McDowell K, Clements JN. How can NSAIDs harm cardiovascular and renal function? *JAAPA.* 2014;27(4):12-15. doi:10.1097/01.JAA.0000444738.62411.83
10. Degenhardt L, Charlson F, Mathers B, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. *Addiction.* 2014;109(8):1320-1333. doi:10.1111/add.12551
11. Volkow ND, Icaza MEM, Poznyak V, Saxena S, Gerra G, UNODC-WHO Informal Scientific Network. Addressing the opioid crisis globally. *World Psychiatry.* 2019;18(2):231-232. doi:10.1002/wps.20633
12. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. *Pain Physician.* 2008;11(2 Suppl):S105-20.
13. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain.* 2015;156(4):569-576. doi:10.1097/01.j.pain.0000460357.01998.f1
14. Lucas P. Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain. *J Psychoactive Drugs.* 2012;44(2):125-133. doi:10.1080/02791072.2012.684624
15. Bonini SA, Premoli M, Tambaro S, et al. Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. *J Ethnopharmacol.* 2018;227:300-315. doi:10.1016/j.jep.2018.09.004
16. Lynch ME. Cannabinoids in the management of chronic pain: a front line clinical perspective. *J Basic Clin Physiol Pharmacol.* 2016;27(3):189-191. doi:10.1515/jbcpp-2015-0059
17. Fitzcharles MA, Baerwald C, Ablin J, Hauser W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. *Schmerz.* 2016;30(1):47-61. doi:10.1007/s00482-015-0084-3
18. Hauser W, Petzke F, Fitzcharles MA. Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - an overview of systematic reviews. *Eur J Pain.* 2018;22(3):455-470. doi:10.1002/ejp.1118
19. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA.* 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
20. Chaves C, Bittencourt PCT, Pelegrini A. Ingestion of a THC-Rich Cannabis Oil in People with Fibromyalgia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Pain Med.* 2020;21(10):2212-2218. doi:10.1093/pm/pnaa303

21. Vickery AW, Finch PM. Cannabis: are there any benefits? *Intern Med J*. 2020;50(11):1326-1332. doi:[10.1111/imj.15052](https://doi.org/10.1111/imj.15052)
22. Almog S, Aharon-Peretz J, Vulfsons S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. *Eur J Pain*. 2020;24(8):1505-1516. doi:[10.1002/ejp.1605](https://doi.org/10.1002/ejp.1605)
23. Hosseini A, McLachlan AJ, Lickliter JD. A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. *Br J Clin Pharmacol*. 2021;87(4):2070-2077. doi:[10.1111/bcp.14617](https://doi.org/10.1111/bcp.14617)
24. Izgelov D, Davidson E, Barasch D, Regev A, Domb AJ, Hoffman A. Pharmacokinetic investigation of synthetic cannabidiol oral formulations in healthy volunteers. *Eur J Pharm Biopharm*. 2020;154:108-115. doi:[10.1016/j.ejpb.2020.06.021](https://doi.org/10.1016/j.ejpb.2020.06.021)
25. Perkins D, Butler J, Ong K, et al. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. *Eur J Drug Metab Pharmacokinet*. 2020;45(5):575-586. doi:[10.1007/s13318-020-00624-6](https://doi.org/10.1007/s13318-020-00624-6)
26. Vazquez M, Guevara N, Maldonado C, Guido PC, Schaiquevich P. Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain. *Biomed Res Int*. 2020;2020:3902740. doi:[10.1155/2020/3902740](https://doi.org/10.1155/2020/3902740)
27. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. *Int J Mol Sci*. 2018;19(3). doi:[10.3390/ijms19030833](https://doi.org/10.3390/ijms19030833)
28. Starowicz K, Finn DP. Cannabinoids and Pain: Sites and Mechanisms of Action. *Adv Pharmacol*. 2017;80:437-475. doi:[10.1016/bs.apha.2017.05.003](https://doi.org/10.1016/bs.apha.2017.05.003)
29. Silver RJ. The Endocannabinoid System of Animals. *Animals (Basel)*. 2019;9(9). doi:[10.3390/ani9090686](https://doi.org/10.3390/ani9090686)
30. Chavez AE, Chiu CQ, Castillo PE. TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. *Nat Neurosci*. 2010;13(12):1511-1518. doi:[10.1038/n.2684](https://doi.org/10.1038/nn.2684)
31. Demuth DG, Molleman A. Cannabinoid signalling. *Life Sci*. 2006;78(6):549-563. doi:[10.1016/j.lfs.2005.05.055](https://doi.org/10.1016/j.lfs.2005.05.055)
32. Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. *Cell Mol Life Sci*. 2016;73(23):4449-4470. doi:[10.1007/s00018-016-2300-4](https://doi.org/10.1007/s00018-016-2300-4)
33. Schmitz K, Mangels N, Haussler A, Ferreiros N, Fleming I, Tegeder I. Pro-inflammatory obesity in aged cannabinoid-2 receptor-deficient mice. *Int J Obes (Lond)*. 2016;40(2):366-379. doi:[10.1038/ijo.2015.169](https://doi.org/10.1038/ijo.2015.169)
34. Singh UP, Singh NP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS. Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10(-/-) mice by attenuating the activation of T cells and promoting their apoptosis. *Toxicol Appl Pharmacol*. 2012;258(2):256-267. doi:[10.1016/j.taap.2011.11.005](https://doi.org/10.1016/j.taap.2011.11.005)
35. Shang Y, Tang Y. The central cannabinoid receptor type-2 (CB2) and chronic pain. *Int J Neurosci*. 2017;127(9):812-823. doi:[10.1080/00207454.2016.1257992](https://doi.org/10.1080/00207454.2016.1257992)
36. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-mediated control of synaptic transmission. *Physiol Rev*. 2009;89(1):309-380. doi:[10.1152/physrev.00019.2008](https://doi.org/10.1152/physrev.00019.2008)
37. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. Endocannabinoid signaling and synaptic function. *Neuron*. 2012;76(1):70-81. doi:[10.1016/j.neuron.2012.09.020](https://doi.org/10.1016/j.neuron.2012.09.020)
38. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. *Pain*. 2008;139(1):225-236. doi:[10.1016/j.pain.2008.04.006](https://doi.org/10.1016/j.pain.2008.04.006)
39. Huang SM, Bisogno T, Petros TJ, et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. *J Biol Chem*. 2001;276(46):42639-42644. doi:[10.1074/jbc.M107351200](https://doi.org/10.1074/jbc.M107351200)
40. Scavone JL, Sterling RC, Van Bockstaele EJ. Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. *Neuroscience*. 2013;248:637-654. doi:[10.1016/j.neuroscience.2013.04.034](https://doi.org/10.1016/j.neuroscience.2013.04.034)
41. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT1a receptors. *Neurochem Res*. 2005;30(8):1037-1043. doi:[10.1007/s11064-005-6978-1](https://doi.org/10.1007/s11064-005-6978-1)

42. O'Sullivan SE. An update on PPAR activation by cannabinoids. *Br J Pharmacol*. 2016;173(12):1899-1910. doi:10.1111/bph.13497
43. Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. *Pharmacol Res*. 2017;119:358-370. doi:10.1016/j.phrs.2017.02.022
44. Morales P, Hurst DP, Reggio PH. Molecular Targets of the Phytocannabinoids: A Complex Picture. *Prog Chem Org Nat Prod*. 2017;103:103-131. doi:10.1007/978-3-319-45541-9_4
45. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. *Cannabis Cannabinoid Res*. 2017;2(1):139-154. doi:10.1089/can.2016.0034
46. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants (Basel)*. 2019;9(1). doi:10.3390/antiox9010021
47. Ke P, Shao BZ, Xu ZQ, et al. Activation of Cannabinoid Receptor 2 Ameliorates DSS-Induced Colitis through Inhibiting NLRP3 Inflammasome in Macrophages. *PLoS One*. 2016;11(9):e0155076. doi:10.1371/journal.pone.0155076
48. Shao BZ, Wei W, Ke P, Xu ZQ, Zhou JX, Liu C. Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP3 inflammasome. *CNS Neurosci Ther*. 2014;20(12):1021-1028. doi:10.1111/cns.12349
49. Shi CS, Shenderov K, Huang NN, et al. Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. *Nat Immunol*. 2012;13(3):255-263. doi:10.1038/ni.2215
50. Wirth PW, Watson ES, ElSohly M, Turner CE, Murphy JC. Anti-inflammatory properties of cannabichromene. *Life Sci*. 1980;26(23):1991-1995. doi:10.1016/0024-3205(80)90631-1
51. Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. *FASEB J*. 2016;30(11):3682-3689. doi:10.1096/fj.201600646R
52. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. *J Immunol*. 2004;173(4):2373-2382. doi:10.4049/jimmunol.173.4.2373
53. Lu T, Newton C, Perkins I, Friedman H, Klein TW. Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. *J Pharmacol Exp Ther*. 2006;319(1):269-276. doi:10.1124/jpet.106.108381
54. Parker J, Atez F, Rossetti RG, Skulas A, Patel R, Zurier RB. Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. *Rheumatol Int*. 2008;28(7):631-635. doi:10.1007/s00296-007-0489-0
55. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. *Glia*. 2000;29(1):58-69.
56. Fiani B, Sarhadi KJ, Soula M, Zafar A, Quadri SA. Current application of cannabidiol (CBD) in the management and treatment of neurological disorders. *Neurol Sci*. 2020;41(11):3085-3098. doi:10.1007/s10072-020-04514-2
57. Weizman L, Dayan L, Brill S, et al. Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity. *Neurology*. 2018;91(14):e1285-e1294. doi:10.1212/WNL.00000000000006293
58. Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. *Curr Pharm Biotechnol*. 2020;21(5):390-402. doi:10.2174/1389201020666191202111534
59. van Amerongen G, Kanhai K, Baakman AC, et al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. *Clin Ther*. 2018;40(9):1467-1482. doi:10.1016/j.clinthera.2017.01.016
60. Lichtman AH, Lux EA, McQuade R, et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. *J Pain Symptom Manage*. 2018;55(2):179-188 e1. doi:10.1016/j.jpainsymman.2017.09.001
61. Wright P, Walsh Z, Margolese S, et al. Canadian clinical practice guidelines for the use of plant-based cannabis and cannabinoid-based products in the management of chronic non-cancer pain and co-occurring conditions: protocol for a systematic literature review. *BMJ Open*. 2020;10(5):e036114. doi:10.1136/bmjopen-2019-036114

62. Berger AA, Keefe J, Winnick A, et al. Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia. *Best Pract Res Clin Anaesthesiol.* 2020;34(3):617-631. doi:10.1016/j.bpa.2020.08.010
63. van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. *Pain.* 2019;160(4):860-869. doi:10.1097/j.pain.0000000000001464
64. Akram H, Mokrysz C, Curran HV. What are the psychological effects of using synthetic cannabinoids? A systematic review. *J Psychopharmacol.* 2019;33:271-283. doi:10.1177/0269881119826592
65. Karschner EL, Darwin WD, McMahon RP, et al. Subjective and physiological effects after controlled sativex and oral THC administration. *Clin Pharmacol Ther.* 2011;89:400-407. doi:10.1038/clpt.2010.318
66. Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. *Addict Biol.* 2013;18:872-881. doi:10.1111/j.1369-1600.2011.00427.x
67. Jicha CJ, Lofwall MR, Nuzzo PA, Babalonis S, Elayi SC, Walsh SL. Safety of oral dronabinol during opioid withdrawal in humans. *Drug Alcohol Depend.* 2015;157:179-183. doi:10.1016/j.drugalcdep.2015.09.031
68. Hemachandra D, McKetin R, Cherbuin N, Anstey KJ. Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. *Aust N Z J Public Health.* 2016;40:226-230. doi:10.1111/1753-6405.12477
69. Wolff V, Lauer V, Rouyer O, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: a prospective study in 48 consecutive young patients. *Stroke.* 2011;42:1778-1780. doi:10.1161/STROKEAHA.110.610915
70. Ravi D, Ghasemiesfe M, Korenstein D, Cascino T, Keyhani S. Associations between marijuana use and cardiovascular risk factors and outcomes a systematic review. *Ann Intern Med.* 2018;168:187-194. doi:10.7326/M17-1548
71. Gilron I, Blyth FM, Degenhardt L, et al. Risks of harm with cannabinoids, cannabis, and cannabis-based medicine for pain management relevant to patients receiving pain treatment: protocol for an overview of systematic reviews. *Pain Rep.* 2019;4. doi:10.1097/PR9.0000000000000742
72. Korantzopoulos P, Liu T, Papaioannides D, Li G, Goudevenos JA. Atrial fibrillation and marijuana smoking. *Int J Clin Pract.* 2008;62:308-313. doi:10.1111/j.1742-1241.2007.01505.x
73. Coughlin PA, Mavor AID. Arterial Consequences of Recreational Drug Use. *Eur J Vasc Endovasc Surg.* 2006;32:389-396. doi:10.1016/j.ejvs.2006.03.003
74. Ghasemiesfe M, Ravi D, Vali M, et al. Marijuana use, respiratory symptoms, and pulmonary function: a systematic review and meta-analysis. *Ann Intern Med.* 2018;169:106-115. doi:10.7326/M18-0522
75. Martinasek MP, McGrogan JB, Maysonet A. A systematic review of the respiratory effects of inhalational marijuana. *Respir Care.* 2016;61:1543-1551. doi:10.4187/respcare.04846
76. Mehra R, Moore BA, Crothers K, Tetrault J, Fiellin DA. The association between marijuana smoking and lung cancer: a systematic review. *Arch Intern Med.* 2006;166:1359-1367. doi:10.1001/archinte.166.13.1359
77. Tan C, Hatam N, Treasure T. Bullous Disease of the Lung and Cannabis Smoking: Insufficient Evidence for a Causative Link. *J R Soc Med.* 2006;99:77-80. doi:10.1177/014107680609900220
78. Tetrault JM, Crothers K, Moore BA, Mehra R, Concato J, Fiellin DA. Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. *Arch Intern Med.* 2007;167:221-228. doi:10.1001/archinte.167.3.221
79. Borges G, Bagge CL, Orozco R. A literature review and meta-analyses of cannabis use and suicidality. *J Affect Disord.* 2016;195:63-74. doi:10.1016/j.jad.2016.02.007
80. Gobbi G, Atkin T, Zytynski T, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. *JAMA Psychiatry.* 2019;76:426-434. doi:10.1001/jamapsychiatry.2018.4500
81. Amar MB, Potvin S. Cannabis and Psychosis: what is the Link? *J Psychoact Drugs.* 2007;39:131-142. doi:10.1080/02791072.2007.10399871
82. Large M, Sharma S, Compton MT, Slade T, Nielsen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. *Arch Gen Psychiatry.* 2011;68:555-561. doi:10.1001/archgenpsychiatry.2011.5

83. Myles N, Newall H, Nielssen O, Large M. The Association between Cannabis Use and Earlier Age at Onset of Schizophrenia and other Psychoses: Meta-analysis of Possible Confounding Factors. *Curr Pharm Des.* 2012;18:5055-5069. doi:10.2174/13816121280284816
84. Ragazzi TCC, Shuhama R, Menezes PR, Del-Ben CM. Cannabis use as a risk factor for psychotic-like experiences: a systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. *J Early Interv.* 2018;12:1013-1023. doi:10.1111/eip.12693
85. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-Analysis of the association between the level of cannabis use and risk of psychosis. *Schizophr Bull.* 2016;42:1262-1269. doi:10.1093/schbul/sbw003
86. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies. *BMC Psychiatry.* 2014;14. doi:10.1186/1471-244X-14-136
87. Ganzer F, Bröning S, Kraft S, Sack PM, Thomasius R. Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults. *Neuropsychol Rev.* 2016;26:186-222. doi:10.1007/s11065-016-9316-2
88. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. *J Int Neuropsychol Soc.* 2003;9:679-689. doi:10.1017/S1355617703950016
89. Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. *Schizophr Res.* 2011;128:111-116. doi:10.1016/j.schres.2011.02.017
90. Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults A Systematic Review and Meta-analysis. *JAMA Psychiatry.* 2018;75:585-595. doi:10.1001/jamapsychiatry.2018.0335
91. Oomen PP, Van Hell HH, Bossong MG. The acute effects of cannabis on human executive function. *Behav Pharmacol.* 2018;29:605-616. doi:10.1097/FBP.0000000000000426
92. Bogaty SER, Lee RSC, Hickie IB, Hermens DF. Meta-analysis of neurocognition in young psychosis patients with current cannabis use. *J Psychiatr Res.* 2018;99:22-32. doi:10.1016/j.jpsychires.2018.01.010
93. Schoeler T, Monk A, Sami MB, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. *Lancet Psychiatry.* 2016;3:215-225. doi:10.1016/S2215-0366(15)00363-6
94. Platt B, O'Driscoll C, Curran VH, Rendell PG, Kamboj SK. The effects of licit and illicit recreational drugs on prospective memory: a meta-analytic review. *Psychopharmacology.* 2019;236:1131-1143. doi:10.1007/s00213-019-05245-9
95. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. *Exp Clin Psychopharmacol.* 2012;20:420-429. doi:10.1037/a0029117
96. Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. *BMC Cancer.* 2015;15. doi:10.1186/s12885-015-1905-6
97. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between Marijuana Use and Risk of Cancer: A Systematic Review and Meta-analysis. *JAMA Network Open.* 2019;2:1-15. doi:10.1001/jamanetworkopen.2019.16318
98. Calabria B, Degenhardt L, Hall W, Lynskey M. Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. *Drug Alcohol Rev.* 2010;29:318-330. doi:10.1111/j.1465-3362.2009.00149.x
99. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, Zhang ZF. Epidemiologic review of marijuana use and cancer risk. *Alcohol.* 2005;35:265-275. doi:10.1016/j.alcohol.2005.04.008
100. Huang YHJ, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. *Cancer Epidemiol Biomark Prev.* 2015;24:15-31. doi:10.1158/1055-9965.EPI-14-1026
101. Sharapova SR, Phillips E, Sirocco K, Kaminski JW, Leeb RT, Rolle I. Effects of prenatal marijuana exposure on neuropsychological outcomes in children aged 1-11 years: a systematic review. *Paediatr Perinat Epidemiol.* 2018;32:512-532. doi:10.1111/ppe.12505
102. Conner SN, Bedell V, Lipsey K, Macones GA, Cahill AG, Tuuli MG. Maternal Marijuana Use and Adverse Neonatal Outcomes: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2016;128:713-723. doi:10.1097/AOG.0000000000001649

103. Gunn JKL, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. *BMJ Open*. 2016;6:1-8. doi:10.1136/bmjopen-2015-009986
104. Tourné J, Gibaja V, Kahn JP. Acute effects of synthetic cannabinoids: update 2015. *Subst Abuse*. 2017;38:344-366. doi:10.1080/08897077.2016.1219438
105. Courts J, Maskill V, Gray A, Glue P. Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. *Australas Psychiatry*. 2016;24:598-601. doi:10.1177/1039856216663733
106. Haden M, Archer JRH, Dargan PI, Wood DM. MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance. *Subst Use Misuse*. 2017;52:223-232. doi:10.1080/10826084.2016.1223692
107. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. *Clin Toxicol*. 2016;54:1-13. doi:10.3109/15563650.2015.1110590
108. Mansoor K, Kheetan M, Shahnawaz S, et al. Systematic review of nephrotoxicity of drugs of abuse, 2005-2016. *BMC Nephrology*. 2017;18:1-15. doi:10.1186/s12882-017-0794-0
109. Panlilio LV, Goldberg SR, Justinova Z. Cannabinoid Abuse and Addiction: Clinical and Preclinical Findings. *Clin Pharmacol Ther*. 2015;97:616-627. doi:10.1002/cpt.118
110. Budney AJ, Roffman R, Stephens RS, Walker D. Marijuana dependence and its treatment. *Addict Sci Clin Pract*. 2007;4:4-16. doi:10.1151/ASCP07414
111. Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman AH. Marijuana dependence: not just smoke and mirrors. *ILAR Journal*. 2011;52:295-308. doi:10.1093/ilar.52.3.295
112. Patel J, Marwaha R. Cannabis Use Disorder. In: *Clinical Handbook of Adolescent Addiction*. ; 2019:202-212.
113. Degenhardt L, Ferrari AJ, Calabria B, et al. The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. *PLoS ONE*. 2013;8:9-37. doi:10.1371/journal.pone.0076635
114. Freeman TP, Hindocha C, Baio G, et al. Europe PMC Funders Group Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial. 2021;7:865-874. doi:10.1016/S2215-0366(20)30290-X.Cannabidiol
115. Gilbert DG, Rabinovich NE, McDaniel JT. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial. *Psychopharmacology*. 2020;237:1507-1519. doi:10.1007/s00213-020-05476-1
116. Sherman BJ, Caruso MA, McRae-Clark AL. Exogenous progesterone for cannabis withdrawal in women: feasibility trial of a novel multimodal methodology. *Pharmacol Biochem Behav*. 2019;179:22-26. doi:10.1016/j.pbb.2019.01.008
117. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. *JAMA Psychiatry*. 2014;71:281-291. doi:10.1001/jama.psychiatry.2013.3947
118. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. *Psychopharmacology*. 2008;197:157-168. doi:10.1007/s00213-007-1020-8
119. Walther L, Gantner A, Heinz A, Majic T. Evidenzbasierte Behandlungsoptionen der Cannabisabhängigkeit. *Deutsches Arzteblatt International*. 2016;113:653-659. doi:10.3238/arztebl.1.2016.0653
120. Zvonarev V, Fatuki TA, Tregubenko P. The Public Health Concerns of Marijuana Legalization: An Overview of Current Trends. *Cureus*. 2019;11. doi:10.7759/cureus.5806
121. Turner AR, Agrawal S. Marijuana. In: *StatPearls*. StatPearls Publishing; 2020.
122. Breijyeh Z, Jubeh B, Bufo SA, Karaman R, Scranio L. Cannabis: A Toxin-Producing Plant with Potential Therapeutic Uses. *Toxins*. 2021;13:1-2. doi:10.3390/toxins13020117
123. Bahji A, Stephenson C. International perspectives on the implications of cannabis legalization: a systematic review & thematic analysis. *Int J Environ Res Public Health*. 2019;16. doi:10.3390/ijerph16173095
124. Hall W, Lynskey M. Assessing the public health impacts of legalizing recreational cannabis use: the US experience. *World Psychiatry*. 2020;19:179-186. doi:10.1002/wps.20735

125. Leyton M. Cannabis legalization: Did we make a mistake? update 2019. *J Psychiatry Neurosci*. 2019;44:291-293. [doi:10.1503/jpn.190136](https://doi.org/10.1503/jpn.190136)

126. Di Forti M. To legalize or not to legalize cannabis, that is the question! *World Psychiatry*. 2020;19:188-189. [doi:10.1002/wps.20737](https://doi.org/10.1002/wps.20737)